NeuroSigma gets ADHD CE mark; Biotronik launches subQ, implantable heart monitor in EU;

@FierceMedDev: ICYMI: Crime syndicates are hacking devices to steal private medical information for profit. Article | Follow @FierceMedDev

@VarunSaxena2: @HillaryClinton says Medicare should negotiate for lower drug prices. @BernieSanders rips Big Pharma, too. Uh oh! | Follow @VarunSaxena2

@EmilyWFierce: Gilead scores additional indications for Harvoni in hep C, HIV patients. FiercePharma story | Follow @EmilyWFierce

> NeuroSigma's Monarch eTNS System has gotten as CE mark to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children age 7 and older. It said this is the first non-drug ADHD in the E.U. More

> Mallinckrodt Pharmaceuticals ($MNK) gets FDA nod for INOmax DS for infant inhalation therapy during MRI procedures. More

> Biotronik has launched its BioMonitor 2 in Europe for continuous arrhythmia monitoring via a subcutaneous, insertable implant. It has two versions: one for atrial fibrillation and the other for unexplained syncope. More

Biotech News

@FierceBiotech: RIP: Failure-prone KaloBios pulls the plug, calls in the liquidators. More | Follow @FierceBiotech

@JohnCFierce: Did Sanofi ($SNY) drag its feet on Lemtrada to save on the CVR? (Or is it just a lousy drug?). More from the NYT | Follow @JohnCFierce

@DamianFierce: Bloomberg's use of up-style headlines has resulted in a piece of art. Item | Follow @DamianFierce

> Moving on from Novartis, Array inks a $455M oncology deal with Pierre Fabre. Report

> Baxalta wins FDA OK for a long-acting Advate, padding its hemophilia biz. News

> Clovis craters after lung cancer drug hits FDA road block, data deteriorate. Article

Pharma News

@FiercePharma: Bioprinting winning converts in Singapore. FiercePharmaAsia item | Follow @FiercePharma

@EricPFierce: ICYMI: Roche whacking 1,200 jobs, closing plants in US, Ireland, Italy and Spain, but building one in Switzerland. Story | Follow @EricPFierce

@CarlyHFierce: Boehringer ups the ante in IPF drug race with awareness funding. More from FiercePharmaMarketing | Follow @CarlyHFierce

> History suggests a Pfizer-Allergan hookup would mean sizable cuts in manufacturing. Story

> Big three PBMs cut loose more specialty pharmacies as scrutiny grows. Report

> Dealmaking drugmakers 'blacklist' investors to fend off activists. Article

Animal Health News

> Heska beats the Street on revenue and earnings in Q3. More

> Aratana unveils branding and partnering plans at investor day. Report

> Merck reiterates dedication to animal health with Harrisvaccines acquisition. Article

> Phibro seeks growth in aquaculture as Q1 sales growth slows. Story

> ImmuCell soars on Q3 sales growth. Item

Biotech IT News

> Datatrak accused of 'shameless and amateurish scare tactics' as proxy fight turns nasty. Report

> What represents success to 23andMe's Wojcicki? Developing a cure for a major disease. More

> WuXi NextCODE lands starring role in 100,000 Genomes Project. Story

> FDA starts beta testing 'the most advanced bioinformatics platform in the world.' More

> Data-gathering implantable chips to be tested in schizophrenia trial. Article

Pharma Marketing News

> Depomed's staffed-up Nucynta salesforce starts bringing home the bacon. Report

> Merck to forge ahead with CETP-inhibiting cholesterol med. Item

> *NSYNC's Joey Fatone lends pearly whites to Colgate diabetes campaign. Story

> Snafus waiting to happen? Pharma's digital silos stymie end-to-end promo management. More

> Boehringer ups the ante in IPF drug race with awareness funding. Article